欧美最新另类人妖I国产成人av一区二区三区在线观看I九九热精品视频在线观看I国产精品日韩在线I激情av五月婷婷I日韩精品免费

Your Good Partner in Biology Research

  1. Home
  2. 抗體
  3. 科研級生物類似抗體
  4. TPBG (US11008399B2 Biosimilar) Recombinant Monoclonal Antibody

TPBG (US11008399B2 Biosimilar) Recombinant Monoclonal Antibody

  • 貨號：
    CSB-RA024093MB1HU
  • 規格：
    ￥83486
  • 其他：

產品詳情

  • 產品描述：
    TPBG (US11008399B2 Biosimilar Antibody) 重組單克隆抗體是一種針對滋養層糖蛋白（TPBG），其靶點TPBG存在多個別名，包括5T4癌胚抗原、5T4癌胚滋養層糖蛋白、T4癌滋養層糖蛋白、M6P1、Wnt激活抑制因子1（WAIF1）等。該抗體以重組人TPBG蛋白制備，具有明確的抗原特異性，種屬反應性覆蓋人類和恒河猴（Macaca mulatta），為相關研究提供了可靠的工具支持。 靶向TPBG抗體的類似物作為一種針對在多種腫瘤中高表達的癌胚抗原的治療手段，已成為抗腫瘤治療的潛在方向。研究表明，此類藥物通過特異性結合TPBG，抑制腫瘤細胞信號通路（如Wnt通路）或介導抗體依賴的細胞毒性作用（ADCC），從而達到抗腫瘤效果。目前，針對TPBG類似物已進入早期臨床試驗階段，評估其在晚期實體瘤患者中的安全性、藥代動力學特征及初步療效，為后續治療方案優化奠定基礎。 該重組單克隆抗體憑借對人類和恒河猴TPBG的交叉反應性，廣泛應用于腫瘤生物學機制研究和藥物研發。在基礎研究中，可通過實驗，檢測TPBG在正常組織與腫瘤組織中的表達差異，探究其在腫瘤發生發展中的分子機制；在藥物開發中，可用于篩選和驗證TPBG靶向藥物的結合活性、特異性及體外抗腫瘤效果，同時支持恒河猴等非人靈長類動物模型的藥效學和毒理學研究，加速藥物從實驗室到臨床的轉化進程。此外，該抗體還為構建TPBG基因敲除或過表達細胞模型、建立腫瘤異種移植模型等提供了關鍵工具，助力深入解析TPBG的生理功能及臨床轉化價值。
  • Uniprot No.：
  • 基因名：
  • 別名：
    Trophoblast glycoprotein; 5T4 oncofetal antigen; 5T4 oncofetal trophoblast glycoprotein; T4 oncotrophoblast glycoprotein; M6P1; Wnt-activated inhibitory factor 1; WAIF1; TPBG; 5T4
  • 反應種屬：
    Human
  • 免疫原：
    Recombinant Human TPBG protein
  • 免疫原種屬：
    Homo sapiens (Human)
  • 標記方式：
    Non-conjugated
  • 克隆類型：
    Monoclonal
  • 濃度：
    It differs from different batches. Please contact us to confirm it.
  • 保存緩沖液：
    0.01M PBS，pH7.4
  • 產品提供形式：
    Liquid
  • 應用說明：
    Validation Status
    Application-specific performance (e.g., in flow cytometry, ELISA, IHC or other assay formats) has not yet been experimentally verified by CUSABIO. Users are advised to determine the optimal working conditions empirically in their own assay systems.
    Guaranteed Quality
    ① Antibody purity?> 95% tested by SDS-PAGE.
    ② Endotoxin level < 0.1EU/ug tested by LAL method.
  • 儲存條件：
    Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
  • 貨期：
    In stock
  • 用途：
    It is a non-therapeutic biosimilar antibody, owning the same variable region from the corresponding approved therapeutic antibody. In conclusion, it is a research-grade biosimilar antibody and expressed in mammalian cell, which can be directly used as positive controls in drug discovery or used for rapid verification of the biological functions of target protein.

產品評價

靶點詳情

  • 功能：
    May function as an inhibitor of Wnt/beta-catenin signaling by indirectly interacting with LRP6 and blocking Wnt3a-dependent LRP6 internalization.
  • 基因功能參考文獻：
    1. In extravillous trophoblasts, 5T4 may function in epithelial-to-mesenchymal transition during placentation. The role of syncytiotrophoblast 5T4 is unknown, but its abundance in shed syncytial vesicles may signify route of sensitization of the maternal immune system. PMID: 28481180
    2. Collectively, these findings demonstrate that an anti-5T4 antibody-drug conjugate reduces the fraction of cancer stem cells (CSC), and prevents local recurrence and suggest a novel therapeutic approach for patients with head and neck squamous cell carcinoma. PMID: 27780858
    3. We obtained GWS evidence (P < 2.7 x 10(-6)) for gene-based association in the total sample with a novel locus, TPBG (P = 1.8 x 10(-6)). PMID: 28183528
    4. In conclusion, the present study provided evidence that TPBG is involved in PDAC metastasis, and that TPBG and its associated signaling pathways may be a suitable target for pancreatic ductal adenocarcinoma therapy. PMID: 25738465
    5. 5T4 expression is mechanistically associated with the directional movement of cells through epithelial mesenchymal transition, facilitation of CXCL12/CXCR4 chemotaxis, blocking of canonical Wnt/beta-catenin while favouring non-canonical pathway signalling PMID: 25066861
    6. Tyrosine 325 plus the leucine-rich repeat 1 surface centered on a second exposed aromatic residue, phenylalanine 97, are essential for inhibition of Wnt/beta-catenin signaling. PMID: 24582434
    7. The surface expression of 5T4 marks the use of the CXCR4 rather than the CXCR7 receptor, with distinct consequences for CXCL12 exposure. PMID: 22956548
    8. 5T4 is a potential new antigen for targeted therapies such as immunotherapy in MPM, as it is overexpressed on mesothelioma cells and recognised by 5T4-specific cytotoxic T-cells. PMID: 22498111
    9. Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen PMID: 11903056
    10. Results sugest that 5T4 is a transient marker of human embryonic stem cell differentiation & that 5T4 phenotype, colony seeding density and culture conditions influence the maintenance of pluripotent hES cells and their differentiation to neural lineages. PMID: 16616918
    11. there is a repertoire of CD8 T cell recognition of 5T4 in normal human donors and some candidate HLA-A*0201 epitopes have been identified PMID: 16646078
    12. the mRNA expression of trophoblast glycoprotein is up-regulated in cells circulating within blood from women with preeclampsia. PMID: 17978129
    13. 5T4-based cancer vaccine: cytotoxic T lymphocyte epitopes identified in Trovax-vaccinated colorectal cancer patients PMID: 18567615
    14. colorectal cancer patients who had preexisting cell proliferative responses to 5T4 were longer-term survivors PMID: 18833005

    顯示更多

    收起更多

  • 亞細胞定位：
    Cell membrane; Single-pass type I membrane protein.
  • 組織特異性：
    Expressed by all types of trophoblasts as early as 9 weeks of development. Specific for trophoblastic cells except for amniotic epithelium. In adult tissues, the expression is limited to a few epithelial cell types but is found on a variety of carcinoma.
  • 數據庫鏈接：

    HGNC: 12004

    OMIM: 190920

    KEGG: hsa:7162

    STRING: 9606.ENSP00000358765

    UniGene: Hs.71947



×
生命科學計算平臺